A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Part of paid clinical trials in Greenbrae, California.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT07169851
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Drug-Related Side Effects and Adverse Reactions
- Nausea
- Neoplasms
- Vomiting
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- LY3537021 — DRUGAdministered SC
- Placebo — DRUGAdministered SC
- Standard of Care Antiemetic Therapies — DRUG5-HT3 Receptor Antagonist, NK1 Receptor Antagonist, Dexamethasone administered orally, IV, or transdermally
- Background Chemotherapy — DRUGCisplatin or anthraxyline and cyclophosphamide (AC) administered IV
Study Details
The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy. Participants who join this study will be in it until all parts are finished, which could take about 2 months.
Key Dates
- Start date
- Nov 28, 2025
- Status verified
- Jun 2026
- Primary completion
- Dec 31, 2026
- Completion
- Feb 28, 2027
Study Design
- Enrollment
- 204 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: LY3537021 + Antiemetic TherapiesPrior to chemotherapy, participants receive LY3537021 administered subcutaneously (SC) with standard of care (SOC) antiemetic therapies orally, intravenously (IV), or transdermally, per local label
- Placebo Comparator: Placebo + Antiemetic TherapiesPrior to chemotherapy, participants receive placebo administered SC with SOC antiemetic therapies orally, IV, or transdermally, per local label
Primary Outcome Measure
Proportion of Participants with a Complete Response (CR) in the Delayed Phase of CINV [ Time Frame: 24 to 120 hours after first chemotherapy infusion ]
Central Contacts
- Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or1-317-615-4559
- Physicians interested in becoming principal investigators please contact
Locations (19)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Marin Cancer Care | Greenbrae | California | 94904 | Cyrus Mazidi (PRINCIPAL_INVESTIGATOR) |
| City of Hope Orange County Lennar Foundation Cancer Center | Irvine | California | 92618 | 714-252-9415 Sudarsan Kollimuttathuillam (PRINCIPAL_INVESTIGATOR) |
| Cancer and Blood Specialty Clinic | Los Alamitos | California | 90720 | Nihal Abdulla (PRINCIPAL_INVESTIGATOR) |
| BASS Cancer Center | Walnut Creek | California | 94598 | Jewel Johl (PRINCIPAL_INVESTIGATOR) |
| UCHealth Harmony | Fort Collins | Colorado | 80528 | 970-297-6150 Steven Schuster (PRINCIPAL_INVESTIGATOR) |
| Clavis Medical | Miami Lakes | Florida | 33014 | 786-723-4001 Eloy Roman (PRINCIPAL_INVESTIGATOR) |
| BRCR Global - Tamarac | Tamarac | Florida | 33321 | 561-477-0614 Chintan Gandhi (PRINCIPAL_INVESTIGATOR) |
| Summit Cancer Care, PC | Savannah | Georgia | 31405 | 912-651-5771 Michael Chahin (PRINCIPAL_INVESTIGATOR) |
| Hope and Healing Cancer Services | Hinsdale | Illinois | 60521 | 630-560-0121 Srilata Gundala (PRINCIPAL_INVESTIGATOR) |
| Indiana University Health University Hospital | Indianapolis | Indiana | 46202 | Tarah Ballinger (PRINCIPAL_INVESTIGATOR) |
| North Mississippi Hematology and Oncology Associates | Tupelo | Mississippi | 38801 | Amit Jain (PRINCIPAL_INVESTIGATOR) |
| Laura and Isaac Perlmutter Cancer Center | New York | New York | 10016 | Olivia Seecof (PRINCIPAL_INVESTIGATOR) |
| Oncology Specialists of Charlotte | Charlotte | North Carolina | 28207 | 704-342-1900 Justin Favaro (PRINCIPAL_INVESTIGATOR) |
| Southern Oncology Specialists | Huntersville | North Carolina | 28078 | William Mitchell (PRINCIPAL_INVESTIGATOR) |
| Asante Rogue Regional Medical Center | Medford | Oregon | 97504 | 541-789-5003 Alison Savage (PRINCIPAL_INVESTIGATOR) |
| World Research Link | Baytown | Texas | 77521 | 833-832-8328 Amir Rasheed (PRINCIPAL_INVESTIGATOR) |
| John Peter Smith Hospital | Fort Worth | Texas | 76104 | 817-702-8049 Kalyani Narra (PRINCIPAL_INVESTIGATOR) |
| Community Cancer Trials of Utah | Ogden | Utah | 84405 | 801-689-3909 Carl Gray (PRINCIPAL_INVESTIGATOR) |
| Cancer Care Northwest | Spokane | Washington | 99202 | Saritha Thumma (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Greenbrae, CA
Related Studies
- Novel Serum Markers for Monitoring Response to Anti-Cancer TherapyRecruiting · Stanford University · Stanford, California
- Collection of Tissue Samples for Cancer ResearchRecruiting · National Cancer Institute (NCI) · Sacramento, California
- Registry Study for Radiation Therapy OutcomesRecruiting · Proton Collaborative Group · Scottsdale, Arizona
- RSSearch Patient Registry-Long Term Study of Use of SRS/SBRTRecruiting · The Radiosurgery Society · Colorado Springs, Colorado